Fibroblast growth factor receptor inhibitors: patent review (2015–2019)

References

• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–149.
   PubMed Web of Science ®Google Scholar
• Sleeman M, Fraser J, Mcdonald M, et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001;271:171–182.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–266.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005;16:107–137.
   PubMed Web of Science ®Google Scholar
• Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281:6120–6123.
   PubMed Web of Science ®Google Scholar
• Richter B, Faul C. FGF23 actions on target tissues—with and without Klotho. Front Endocrinol (Lausanne). 2018;9:1–21.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, et al. receptor specificity of the fibroblast growth factor family THE COMPLETE MAMMALIAN FGF FAMILY. J Biol Chem. 2006;281:15694–15700.
   PubMed Web of Science ®Google Scholar
• Hart KC, Scott C. Robertson and DJD. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell. 2001;12:931–942.
   PubMed Web of Science ®Google Scholar
• Lavallee TM, Prudovsky IA, Mcmahon GA, et al. Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the src pathway correlates with migration. J Cell Biol. 1998;141:1647–1658.
   PubMed Web of Science ®Google Scholar
• Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci. 1999;4:165–177.
   PubMedGoogle Scholar
• Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000;19:3309–3320.
   PubMed Web of Science ®Google Scholar
• Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052–16074.
   PubMedGoogle Scholar
• Cihoric N, Savic S, Schneider S, et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer. 2014;110:2914–2922.
   PubMed Web of Science ®Google Scholar
• Sergio Reis-Filho J, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutictarget for lobular breast Carcinomas. Clin Cancer Res. 2006;12:6652–6662.
   PubMed Web of Science ®Google Scholar
• Pearson A, Smyth E, Babina IS, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 2016;6:838–851.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Ercan D, Capelletti M, et al. Identification of Oncogenic And Drug-Sensitizing Mutations In The Extracellular Domain Of FGFR2. Cancer Res. 2015;75:3139–3146.
   PubMed Web of Science ®Google Scholar
• Dodurga Y, Tataroglu C, Kesen Z, et al. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res. 2011;10:86–95.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Publ Gr. 1997;16:260–264.
   Google Scholar
• Takeda M, Arao T, Yokote H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res. 2007;13:3051–3057.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen T-H, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci. 2008;105:8713–8717.
   PubMed Web of Science ®Google Scholar
• Ishiwata T. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Front Biosci. 2018;23:626–639.
   PubMed Web of Science ®Google Scholar
• Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
   PubMed Web of Science ®Google Scholar
• Wu Y-M, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–647.
   PubMed Web of Science ®Google Scholar
• Ronca R, Di SE, Giacomini A, et al. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Res. 2013;12:2760–2771.
   Google Scholar
• Marek L, Ware KE, Fritzsche A, et al. Fibroblast Growth Factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009;75:196–207.
   PubMed Web of Science ®Google Scholar
• Aukes K, Forsman C, Brady NJ, et al. Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions. PloS One. 2017;12:e0185736.
   PubMed Web of Science ®Google Scholar
• Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86:356–361.
   PubMed Web of Science ®Google Scholar
• Ruotsalainen T, Joensuu H, Mattson K, et al. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1492–1495.
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008;27:85–97.
   PubMed Web of Science ®Google Scholar
• Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem. 2010;285:5165–5170.
   PubMed Web of Science ®Google Scholar
• Ronca R, Giacomini A, Rusnati M, et al. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin Ther Targets. 2015;19:1361–1377.
   PubMed Web of Science ®Google Scholar
• Presta M, Dell’Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159–178.
   PubMed Web of Science ®Google Scholar
• Lieu C, Heymach J, Overman M, et al. Beyond VEGF: inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res. 2011;17:6130–6139.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39.
   PubMed Web of Science ®Google Scholar
• Renhowe PA, Pecchi S, Shafer CM, et al. Design, structure-activity relationships and in vivo characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: novel class of receptor tyrosine kinase inhibitors. J Med Chem. 2009;52:278–292.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58:1053–1063.
   PubMed Web of Science ®Google Scholar
• Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459–5465.
   PubMed Web of Science ®Google Scholar
• Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2- b]pyridazin-3-yl)ethynyl]-4-methyl- N -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase. J Med Chem. 2010;53:4701–4719.
   PubMed Web of Science ®Google Scholar
• Hall TG, Yu Y, Eathiraj S, et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One. 2016;11:3–5.
   Web of Science ®Google Scholar
• Watanabe Miyano S, Yamamoto Y, Kodama K, et al. E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models. Mol Cancer Ther. 2016;15:2630–2639.
   PubMed Web of Science ®Google Scholar
• Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Publ Gr. 2017;17:318–332.
   Google Scholar
• Hierro C, Rodon J, Tabernero J. Fibroblast Growth Factor (FGF) Receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors. Semin Oncol. 2015;42:801–819.
   PubMed Web of Science ®Google Scholar
• Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med. 2016;38:3–15.
   PubMed Web of Science ®Google Scholar
• Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72:2045–2056.
   PubMed Web of Science ®Google Scholar
• Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54:7066–7083.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. Embo J. 1998;17:5896–5904.
   PubMed Web of Science ®Google Scholar
• Zhao G, Li W-Y, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011;10:2200–2210.
   PubMed Web of Science ®Google Scholar
• Ebiike H, Taka N, Matsushita M, et al. Discovery of [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), an orally available and selective Fibroblast Growth Factor Receptor (FGFR) inhibitor. J Med Chem. 2016;59:10586–10600.
   PubMed Web of Science ®Google Scholar
• Futami T, Okada H, Kihara R, et al. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma. Mol Cancer Ther. 2017;16:68–75.
   PubMed Web of Science ®Google Scholar
• Kameda M Astellas pharma inc., Kotobuki pharmaceutical co. Nitrogen-containing aromatic heterocyclic compounds. WO2013129369. 2013.
   Google Scholar
• Collin MP, Lobell M, Hübsch W, et al. Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor. ChemMedChem. 2018;13:437–445.
   PubMed Web of Science ®Google Scholar
• BROHM D, HEROULT M, COLLIN M-P, et al. Bayer pharma aktiengesellschaft disubstituted benzothienyl-pyrrolotriazines and their use as Fgfr kinase inhibitors. WO2013087578. 2013.
   Google Scholar
• Nogova L, Sequist LV, Garcia JMP, et al. Evaluation of BGJ398, a Fibroblast growth factor receptor 1-3 kinase inhibitor, in patientswith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion stud. J Clin Oncol. 2017;35:157–165.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33:3401–3408.
   PubMed Web of Science ®Google Scholar
• Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16:1010–1020.
   PubMed Web of Science ®Google Scholar
• Markham A. Erdafitinib: first Global Approval. Drugs. 2019;79:1017–1021.
   PubMed Web of Science ®Google Scholar
• Zuccotto F, Ardini E, Casale E, et al. Through the “ gatekeeper door ”: exploiting the active kinase conformation. J Med Chem. 2010;53:2681–2694.
   Google Scholar
• Sohl CD, Ryan MR, Luo B, et al. Illuminating the molecular,mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles’ heel of targeted therapy. ACS Chem Biol. 2015;10:1319–1329.
   PubMed Web of Science ®Google Scholar
• Chell V, Balmanno K, Little AS, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2012;32:3059–3070.
   PubMed Web of Science ®Google Scholar
• Byron SA, Chen H, Wortmann A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib and ponatinib ATP-competitive inhibitors. Neoplasia. 2013;15:975–988.
   PubMed Web of Science ®Google Scholar
• Zhou W, Hur W, McDermott U, et al. A Structure-Guided Approach to Creating Covalent FGFR Inhibitors. Chem Biol. 2010;17:285–295.
   PubMedGoogle Scholar
• Azam M, Seeliger MA, Gray NS, et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15:1109–1118.
   PubMed Web of Science ®Google Scholar
• Ryan MR, Christal D, Sohl BL, et al. The FGFR1 V561M Gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT. Mol Cancer Res. 2018. DOI:10.1158/1541-7786.MCR-18-0429.
   Web of Science ®Google Scholar
• Tan L, Wang J, Tanizaki J, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci. 2014;111:E4869–E4877.
   PubMed Web of Science ®Google Scholar
• Sootome H, Fujioka Y, Miura A, et al. Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors. Mol Cancer Ther. 2013;12:A271 LP–A271.
   Web of Science ®Google Scholar
• Sagara T, Ito S, Otsuki S, et al. Taiho pharmaceutical Co. 3,5-disubstituted alkynylbenzene compound and salt thereof. WO2013108809. 2013.
   Google Scholar
• Hagel M, Miduturu C, Sheets M, et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular Carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 2015;5:424–437.
   PubMed Web of Science ®Google Scholar
• Bifulco NJ, Brooijmans N, Hodous BL, et al. Blueprint medicines corporation. Inhibitors of the fibroblast growth factor receptor. WO2014011900. 2014.
   Google Scholar
• Packer LM, Pollock PM. Paralog-specifi c kinase inhibition of FGFR4 : adding to the arsenal of anti-FGFR agents. Cancer Discov. 2015;5:355–357.
   PubMed Web of Science ®Google Scholar
• Geng M, Liu L, Jiang L, et al. Hanghai Haihe pharmaceutical ltd. Shanghai institute of materia medica, chinese academy of sciences. indazole compounds as fgfr kinase inhibitor, preparation and use thereof. WO2016026445. 2016.
   Google Scholar
• Zhao B, Li Y, Xu P, et al. Discovery of substituted 1H-pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors. ACS Med Chem Lett. 2016;7:629–634.
   PubMed Web of Science ®Google Scholar
• McBride CM, Renhowe PA, Heise C, et al. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006;16:3595–3599.
   PubMed Web of Science ®Google Scholar
• Duan W, Geng M, Yan W, et al. Shanghai institute of materia medica, Chinese academy of sciences. Method for preparing indazole compound and use thereof. WO2017008708. 2017.
   Google Scholar
• Yan W, Wang X, Dai Y, et al. Discovery of 3-(5′-substituted)-benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as potent fibroblast growth factor receptor inhibitors: design, synthesis, and biological evaluation. J Med Chem. 2016;59:6690–6708.
   PubMed Web of Science ®Google Scholar
• Liu H, Geng M, Zhu W, et al. Shanghai institute of materia medica, Chinese academy of sciences. Pyrazolophenyl-pyridine compound, pharmaceutical composition comprising same, and use thereof. WO2016188481. 2016.
   Google Scholar
• Zhu W, Chen H, Wang Y, et al. Design, synthesis, and pharmacological evaluation of novel multisubstituted pyridin-3-amine derivatives as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer. J Med Chem. 2017;60:6018–6035.
   PubMed Web of Science ®Google Scholar
• Zhang A, Geng M, Xing L, et al. Institute of materia medica, chinese academy of sciences. Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof. WO2017140269. 2017.
   Google Scholar
• Setsuo F, Toshimi O, Keigo T, et al. Eisai R&D management Co., Ltd Monocyclic pyridine derivative. US20140235614. 2014.
   Google Scholar
• Wei M, Peng X, Xing L, et al. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors. Eur J Med Chem. 2018;154:9–28.
   PubMed Web of Science ®Google Scholar
• Jiang XF, Dai Y, Peng X, et al. SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. Acta Pharmacol Sin. 2018;39:243–250.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang J, Ding L et al. Betta pharmaceuticals ltd. Fgfr inhibitor and application thereof. WO2018153373. 2018.
   Google Scholar
• Zhang H, Liu S Hangzhou innogate pharma ltd. Heterocyclic compound used as FGFR inhibitor: WO2017118438. 2017.
   Google Scholar
• Yen Y, J-P L, Chen C-H Taipei medical university. Chlorobenzene substituted azaaryl compounds. WO2017015400. 2017.
   Google Scholar
• Chen C, Liu Y, Pan S, et al. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget. 2016;7:26374–26387.
   PubMedGoogle Scholar
• Chen C, Changou CA, Hsieh T, et al. Dual inhibition of PIK3C3 and FGFR as a new therapeutic approach to treat bladder cancer. Clin Cancer Res. 2018;24:1176–1190.
   PubMed Web of Science ®Google Scholar
• Greff Z, Kéri G, Örfi L, et al. Vichem chemie kutató kft. Benzo[b]thiophene derivatives and their use for the inhibition of fibroblast growth factor receptor kinases (FGFRs) for the use of neo- and hyperplasia therapies. WO2017153789. 2017.
   Google Scholar
• Sootome H Taiho pharmaceutical ltd. Therapeutic agent for FGFR inhibitor-resistant cancer. WO2015008844. 2015.
   Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9:1064–1079:CD-19-0182.
   PubMedGoogle Scholar
• Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS‐120 cancer target binding: defining reactivity and revealing the first Fibroblast Growth Factor Receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14:494–500.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Chen L, et al. Medshine discovery Inc. FGFR inhibitors. WO2018121650. 2018.
   Google Scholar
• Kong NX, Zhou C, Chen X. Guangzhou innocare pharma, ltd. Heterocyclic compound as FGFR inhibitor: WO2018028438. 2018.
   Google Scholar
• Xiangyang C, Yiagxiang G, Xianglong N. Beijing innocare pharma. Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof. US20190210997. 2019.
   Google Scholar
• Duan W, Geng M, Wang Y, et al. Shanghai institute of materia medica, chinese academy of sciences. New compound having fgfr inhibitory activity and preparation and application thereof. WO2017215485. 2017.
   Google Scholar
• Wang Y, Dai Y, Wu X, et al. Discovery and development of a series of pyrazolo[3,4-d]pyridazinone compounds as the novel covalent fibroblast growth factor receptor inhibitors by the rational drug design. J Med Chem. 2019;62:7473–7488.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Fan J, et al. Discovery of potent irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) inhibitors. J Med Chem. 2018;61:9085–9104.
   PubMedGoogle Scholar
• Verner E, Brameld KA, Biopharma P. Quinolone derivatives as fibroblast growth factor receptor inhibitors. WO2015120049. 2015.
   Google Scholar
• Brameld KA, Owens TD, Verner E, et al. Discovery of the irreversible covalent FGFR inhibitor 8‑(3-(4- Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)- 2-(methylamino)pyrido[2,3‑d]pyrimidin-7(8H)‑one (PRN1371) for the treatment of solid tumors. J Med Chem. 2017;60:6516–6527.
   PubMed Web of Science ®Google Scholar
• Venetsanakos E, Brameld KA, Phan VT, et al. The irreversible covalent fibroblast growth factor receptor inhibitor PRN1371 exhibits sustained inhibition of FGFR after drug clearance. Mol Cancer Ther. 2017;16:2668–2677.
   PubMed Web of Science ®Google Scholar
• Bradshaw JM, Mcfarland JM, Paavilainen VO, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitor. Nat Chem Biol. 2015;11:525.
   PubMed Web of Science ®Google Scholar
• Brameld KA, Verner E. Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor receptor inhibitors. WO2016191172. 2016.
   Google Scholar
• Patterson AV, Smaill JB, Ashoorzadeh A, et al. Auckland uniservices limited, Guangzhou institut. FGFR kinase inhibitors and pharmaceutical uses. WO2018160076. 2018.
   Google Scholar
• WU F. Nanjing transthera biosciences. Fibroblast growth factor receptor inhibitor and use thereof. WO2019029541. 2019.
   Google Scholar
• Li X, Guise CP, Taghipouran R, et al. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Eur J Med Chem. 2017;135:531–543.
   PubMed Web of Science ®Google Scholar
• French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012;7:1–12.
   Web of Science ®Google Scholar
• Quintanal-Villalonga A, Ferrer I, Molina-Pinelo S, et al. A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opin Ther Pat. 2007;29:429–438.
   Google Scholar
• Fairhurst RA, Knoepfel T, Leblanc C, et al. Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region. Medchemcomm. 2017;8:1604–1613.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xu F, Dominguez NP, et al. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Mol Carcinog. 2018;57:1616–1625.
   PubMed Web of Science ®Google Scholar
• Bifulco NJ, Dipietro LV, Hodous BL, et al. Blueprint medicines corporation. Inhibitors of the fibroblast growth factor receptor. WO2015061572. 2015.
   Google Scholar
• D’Agostino LA, Sjin RTT, Niu D, et al. Celgene avilomics research, Sanofi. Heteroaryl compounds and uses thereof. WO2014144737. 2014.
   Google Scholar
• Lee MS, Byun EY, Kim JS, et al. Hanmi pharmaceutical ltd. Novel heterocyclic derivative compound and use thereof. WO2018004258. 2018.
   Google Scholar
• Lu L, Wu L, Shen B, et al. Incyte corporation. Bicyclic heterocycles as FGFR4 inhibitors. WO2016134294. 2016.
   Google Scholar
• Reynolds D, Hao M, Wang J, et al. Eisai R&D management ltd. Fgfr4 inhibitors. WO2015057963. 2015.
   Google Scholar
• Reynolds D, Hao M, Wang J, et al. Eisai R&D management ltd. Pyrimidine FGFR4 inhibitors. WO2015057938. 2015.
   Google Scholar
• Reynolds D, Hao M, Wang J, et al. Eisai R&D management ltd. Fgfr4 inhibitors. WO2016164703. 2016.
   Google Scholar
• Joshi JJ, Coffey H, Corcoran E, et al. H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular Carcinoma. Cancer Res. 2017;77:6999–7014.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Z, Dai M, et al. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping. Bioorg Med Chem Lett. 2017;27:2420–2423.
   PubMed Web of Science ®Google Scholar
• Chen L, Guan D, Bai H, et al. Zhejiang Hisun Pharmaceutical Co. Pyrimidine derivative, method for preparing same and use thereof in medicine. WO2017198221. 2017.
   Google Scholar
• Chen Z, Long C, Zhang Y, et al. Guangdong Zhongsheng pharmaceutical ltd, medshine discovery Inc. FGFR4 inhibitor and preparation method and use thereof. WO2018090973. 2018.
   Google Scholar
• Mo C, Zhang Z, Guise CP, et al. 2‑Aminopyrimidine derivatives as new selective fibroblast growth factor receptor 4 (FGFR4) inhibitors. ACS Med Chem Lett. 2017;8:543–548.
   PubMed Web of Science ®Google Scholar
• Shao N, Yuan H, Wang D, et al. Bioardis. Aromatic ether derivative, preparation method therefor, and medical applications thereof. WO2018072707. 2018.
   Google Scholar
• Knoepfel T, Furet P, Mah R, et al. 2-Formylpyridyl ureas as highly selective reversible-covalent inhibitors of fibroblast growth factor receptor 4. ACS Med Chem Lett. 2018;9:215–220.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang H Shanghai Zheye Biotechnology llc. Compound for selectively inhibiting kinase and use thereof. WO2018121774. 2018.
   Google Scholar
• Li X, He L, Chen L, et al. Jiangsu Hansoh Pharmaceutical. FGFR4 inhibitor and prepation method therefor. WO2019085860. 2019.
   Google Scholar
• Zhou C, Zheng C, Zheng Z. Nanjing innocare pharma. Heterocyclic compounds used as FGFR inhibitors. US20190144427. 2019.
   Google Scholar
• Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol. 2005;12:621–637.
   PubMed Web of Science ®Google Scholar
• Jackson PA, Widen JC, Harki DA, et al. Covalent modifiers: A chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-michael addition reactions. J Med Chem. 2017;60:839–885.
   PubMed Web of Science ®Google Scholar
• Fumarola C, Bozza N, Castelli R, et al. Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Front Oncol. 2019;9:179.
   PubMed Web of Science ®Google Scholar
• Blackwell C, Sherk C, Fricko M, et al. Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. Oncotarget. 2016;7:39861–39871.
   PubMed Web of Science ®Google Scholar
• Ronca R, Giacomini A, Di Salle E, et al. Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell. 2015;28:225–239.
   PubMed Web of Science ®Google Scholar
• Herbert C, Schieborr U, Saxena K, et al. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell. 2013;23:489–501.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361.
   PubMed Web of Science ®Google Scholar
• Tejani MA, Cheung E, Eisenberg PD, et al. Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC). J Clin Oncol. 2019;37: 91–91.
   Web of Science ®Google Scholar